CN107410206A - A kind of cad gene PR39 DNA murines - Google Patents
A kind of cad gene PR39 DNA murines Download PDFInfo
- Publication number
- CN107410206A CN107410206A CN201710358833.9A CN201710358833A CN107410206A CN 107410206 A CN107410206 A CN 107410206A CN 201710358833 A CN201710358833 A CN 201710358833A CN 107410206 A CN107410206 A CN 107410206A
- Authority
- CN
- China
- Prior art keywords
- gene
- dna
- egfp
- pcms
- murines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101100244894 Sus scrofa PR39 gene Proteins 0.000 title claims abstract description 117
- 241001529936 Murinae Species 0.000 title claims abstract description 38
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims abstract description 68
- 238000011830 transgenic mouse model Methods 0.000 claims abstract description 54
- 241000699660 Mus musculus Species 0.000 claims abstract description 52
- 241000699666 Mus <mouse, genus> Species 0.000 claims abstract description 32
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 30
- 101150018012 PR39 gene Proteins 0.000 claims abstract description 25
- 230000001408 fungistatic effect Effects 0.000 claims abstract description 15
- 230000010354 integration Effects 0.000 claims abstract description 10
- 210000000349 chromosome Anatomy 0.000 claims abstract description 8
- 108020004414 DNA Proteins 0.000 claims description 52
- 210000004027 cell Anatomy 0.000 claims description 44
- 230000014509 gene expression Effects 0.000 claims description 44
- 241000894006 Bacteria Species 0.000 claims description 43
- 238000001514 detection method Methods 0.000 claims description 33
- 239000013604 expression vector Substances 0.000 claims description 29
- 230000000844 anti-bacterial effect Effects 0.000 claims description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 20
- 241000588724 Escherichia coli Species 0.000 claims description 18
- 230000001580 bacterial effect Effects 0.000 claims description 16
- 108020004999 messenger RNA Proteins 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 235000015097 nutrients Nutrition 0.000 claims description 12
- 238000002474 experimental method Methods 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 9
- 238000003786 synthesis reaction Methods 0.000 claims description 9
- 241000699670 Mus sp. Species 0.000 claims description 8
- 238000011529 RT qPCR Methods 0.000 claims description 7
- 230000003385 bacteriostatic effect Effects 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 7
- 238000004458 analytical method Methods 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 238000012545 processing Methods 0.000 claims description 6
- 108091008146 restriction endonucleases Proteins 0.000 claims description 6
- 238000012795 verification Methods 0.000 claims description 6
- 241000606748 Actinobacillus pleuropneumoniae Species 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 230000009261 transgenic effect Effects 0.000 claims description 5
- 102000016942 Elastin Human genes 0.000 claims description 4
- 108010014258 Elastin Proteins 0.000 claims description 4
- 238000009395 breeding Methods 0.000 claims description 4
- 230000001488 breeding effect Effects 0.000 claims description 4
- 229920002549 elastin Polymers 0.000 claims description 4
- 239000012679 serum free medium Substances 0.000 claims description 4
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 3
- 238000000520 microinjection Methods 0.000 claims description 3
- 230000004044 response Effects 0.000 claims description 3
- 101150036080 at gene Proteins 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000000799 fluorescence microscopy Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 230000035935 pregnancy Effects 0.000 claims description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims 1
- 241000204031 Mycoplasma Species 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 239000005090 green fluorescent protein Substances 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 201000006509 pleuropneumonia Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 13
- 241001465754 Metazoa Species 0.000 abstract description 11
- 230000003115 biocidal effect Effects 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 230000003260 anti-sepsis Effects 0.000 abstract 1
- 230000006641 stabilisation Effects 0.000 abstract 1
- 238000011105 stabilization Methods 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 description 27
- 230000029087 digestion Effects 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 210000000170 cell membrane Anatomy 0.000 description 13
- 238000001890 transfection Methods 0.000 description 13
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000010839 reverse transcription Methods 0.000 description 7
- 108060001132 cathelicidin Proteins 0.000 description 6
- 102000014509 cathelicidin Human genes 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 241000581650 Ivesia Species 0.000 description 5
- 238000004321 preservation Methods 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 4
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 4
- 108010002069 Defensins Proteins 0.000 description 4
- 102000000541 Defensins Human genes 0.000 description 4
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
- 241000607142 Salmonella Species 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000011017 operating method Methods 0.000 description 4
- 239000002574 poison Substances 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000007852 inverse PCR Methods 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 150000003384 small molecules Chemical group 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- 125000003345 AMP group Chemical group 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 235000014683 Hansenula anomala Nutrition 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 description 1
- ICTZKEXYDDZZFP-SRVKXCTJSA-N Pro-Arg-Pro Chemical compound N([C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(O)=O)C(=O)[C@@H]1CCCN1 ICTZKEXYDDZZFP-SRVKXCTJSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000235063 Wickerhamomyces anomalus Species 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000005267 amalgamation Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 229920006227 ethylene-grafted-maleic anhydride Polymers 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000009400 out breeding Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000012372 quality testing Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 108700022109 ropocamptide Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008364 tissue synthesis Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Environmental Sciences (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a kind of cad gene PR39 DNA murines, antibacterial peptide PR39 gene integrations are on No. 13 chromosome of mouse, between GM36264 genes and GM8784 genes, and PR39 genes stabilization can be entailed offspring by the transgenic mice, and can in each tissue of whole body specifically expressing antibacterial peptide PR39 albumen, there is preferable fungistatic effect, and the disease-resistant effect of subjective antisepsis can be played, for being laid a good foundation for follow-up Cecropin-GM gene domestic animal, and a kind of solution of feasibility is provided to reduce the use of antibiotic.
Description
Technical field
The present invention relates to genetic engineering field, more particularly to a kind of cad gene PR39 DNA murines.
Background technology
Antibacterial peptide (Antimicrobial peptides, AMPs) is a kind of micromolecule polypeptide with antibacterial activity, it
It is the important component of body natural immune defence system.Research shows that antibacterial peptide has broader spectrum of compared with antibiotic
Antibacterial ability, but also with the effect such as antiviral, antimycotic, anticancer, it easily by proteolysis, is not easy residual in animal body
Stay, be not easy to make bacterium produce drug resistance, thus by the extensive concern of researcher.
The classification of antibacterial peptide:
Antibacterial peptide can be classified according to the powered situation of molecule, structure and source.Antibacterial peptide is according to molecular band total electrical charge
Situation, can be divided into cationic antibacterial peptide and Anionic Antimicrobial Peptides, and cationic antibacterial peptide accounts for the overwhelming majority;It can be divided according to structure
For polytype, wherein cathelicidins and defensins are main two types;Source can be divided into according to source
In the antibacterial peptide of the biology such as insect, mammal, amphibian, fish, mollusk, shellfish, plant and bacterium.
The molecular structure of antibacterial peptide:
Antibacterial peptide molecular weight is smaller, generally less than 40kD, is generally made up of 20-60 amino acid, and it has different points
Minor structure, including one, two, three and quaternary structure, wherein secondary structure include linear α-helical structure, the foldable structures of β mono-, contained
Stretch the antibacterial peptide of the type of lamellar structure and loop configuration etc. 4.The molecular structure of antibacterial peptide determines its molecular activity, its moderate resistance
The charge number of bacterium peptide institute band, the conserved sequence in molecular structure, α-helical structure, disulfide bond etc. are influence its activity important
Factor.
The mechanism of action of antibacterial peptide:
Antibacterial peptide has broad spectrum antibiotic activity, can effectively suppress bacterium (including gram-positive bacterium and gram-negative
Property bacterium), do not damage eukaryotic.The antibacterial mechanisms of antibacterial peptide are mainly to act on based on bacterial cell membrane, a small number of antibacterials
Peptide can also kill bacterium by suppressing the synthesis of DNA of bacteria, RNA and protein.Antibacterial peptide acts on bacterial cell membrane bag
Include two ways:(1) film destructive mode (membrane disruptive) is the cell membrane of dissolution of bacteria;(2) non-film is destroyed
Sexual norm (non-membrane disruptive) changes the permeability of bacterial cell membrane.
Antibacterial peptide is adsorbed onto on pathogen cell membrane by the electrostatic interaction between pathogen.Bacterial cell membrane contain compared with
More phosphatide, so it is negatively charged, generally can more rapid and better it be adsorbed with cationic antibacterial peptide.Research shows, the suction of antibacterial peptide
Attached effect is also closely related with molecular length itself, and peptide chain is longer in molecular structure, and the difficulty being attached on bacterial cell membrane is got over
Greatly.In contrast, the antibacterial peptide of small molecule structure is more easy to play antibacterial activity.Therefore, there is researcher to attempt reduction long-chain to resist
The peptide chain length of bacterium peptide, it is set to be more easy to be attached on bacterial cell membrane, but such a way may destroy the two level knot of antibacterial peptide
Structure, so as to influence the function of its dissolution of bacteria cell membrane.
Application of the antibacterial peptide in biological medicine and animal husbandry:
With the progress of research, as part important in animal body immune system, it is cured antibacterial peptide in biology
Medicine and animal husbandry show huge application prospect.At present, in human medical field, researcher is by animal sources antibacterial
Peptide is used for clinical test.Colitis clinical model Therapy study proves that cathelicidins antibacterial peptides have fiber reparation work
With the treatment available for IBD.In mouse tuberculosis clinical pattern Therapy study, people's derived antimicrobial peptide LL-37 passes through
The mode of collunarium infects for mouse lung, the results showed that LL-37 can resist tuberculosis.
In livestock-raising, abuse of antibiotics for a long time causes medicine in the generation and livestock and poultry body of drug tolerant bacteria residual
Stay, serious threat is caused to human health so that the research and development of antibacterial peptide substitute antibiotics medicine are highly valued.In recent years
Come, application study of the animal derived antimicrobial peptide in livestock-raising mainly includes following two:(1) improved as feed addictive dynamic
Thing immunity of organisms, promote animal body growth.Show to add antibacterial peptide in Piglet Diets as studied, feed conversion can be improved
Rate, promote piglet growth, while immunity can also be improved.Antibacterial Peptide Extracted from Pig Small Intestine is expelled in SPF level chicken muscles, Ke Yixian
Write and improve efficiency of feed utilization, improve small intestine immunocompetent cell quantity, strengthen the barrier function of enteron aisle.(2) as medicine to dynamic
Thing disease is prevented and treated.Bacteriostatic activity experiment is done using the antibacterial peptide from sheep leucocyte, finds it to pig source
Pathogenic bacteria have good inhibition.It is huge in the Marc-145 cell lines and pig alveolar of infection porcine reproductive and respiratory syndrome virus
The antibacterial peptide PG-1 of continuous addition 36 hours, can substantially suppress the viral infection and duplication in the nutrient solution of phagocyte.
Antibacterial peptide PR-39 is to resist earliest from the small molecule in the isolated Cathelicidin families in the top of chitterlings
Bacterium peptide, then show that PR-39 is also expressed in pig bone marrow primary cell by cDNA clone, and neutrality is stored in propeptide forms
In granulocyte.
Antibacterial peptide PR39 molecular structure feature:
The antibacterial peptide PR-39 assignment of genes gene mapping is in No. 13 chromosomes of pig, mrna length 1784bp, containing in 4 extrons and 3
Containing son, wherein the 4th exons coding antibacterial peptide PR-39 mature peptide.Antibacterial peptide PR39 molecules are made up of 39 amino acid, wherein
There are 22 Pro and 11 Arg, its relative molecular mass is 4719Da.PR39 peptide chain structures order be:
RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPREP, wherein proline tie with the Pro-Arg-Pro that arginine is formed
Structure helps to act on bacterial phospholipid film.The molecular secondary structure of antibacterial peptide PR-39 is linearly changed, and forms α-helical structure.
Antibacterial peptide PR39 mechanism of action:
Antibacterial peptide is broadly divided into two kinds of cathelicidins and defensins according to configuration.Cathelicidins families
Antibacterial peptide relies primarily on to be adsorbed between the positive charge and bacterial cell membrane of arginine residues institute band by the effect of electrostatic attraction
On bacterial cell membrane, its bacteriostasis is played by non-pore-forming pattern formula.Its antibacterial process is not so good as defensins type antibacterial peptides
Rapidly.Defensins directly destroys cell membrane, the synthesis that bacterial cell membrane suppresses DNA and protein is then penetrated, so as to quick
Bacterium is killed, there is stronger killing ability to the bacterium in exponential phase.PR39 belongs to Cathelicidin antibacterial peptides,
It mainly suppresses Gram-negative bacteria, but also has antibacterial effect to small part gram-positive bacteria, plays the machine of bacteriostasis
System is related to its close structure.
A pancreas peptide enzyme recognition site between Pro propetides and PR39 mature peptides in PR39 structures be present, this with PR39 into
The formation of ripe peptide is extracellular relevant with being discharged into.The antibacterial activity of N-terminal peptide chain is lived higher than C-terminal antibacterial in ripe PR39 peptide chain structures
Property, multiple avtive spots be present in the structure of preceding 26 amino acid composition.PR39 different structures bacteriostatic experiment, which is studied, to be shown, PR-15
Fungistatic effect compared with PR39 effect it is even better, PR26 fungistatic effect is similar to PR39, but the peptide chain of different length
It can all be influenceed when playing bacteriostasis by salinity.
Antibacterial peptide PR39 antibacterial action:
Antibacterial peptide PR39 has broad spectrum antibiotic activity, to gram-positive bacteria and Gram-negative bacteria (in addition to pseudomonad)
It is respectively provided with preferable fungistatic effect.There is research by the PR39 gene clonings of synthesis to carrier pHIL-S1, construction recombination plasmid
PHIL-S1-PR39, the plasmid of structure is transformed into saccharomycete, obtains recombinant protein.Restructuring PR39 albumen will be obtained and be used for large intestine
The bacteriostatic experiment of bacillus, Salmonella typhimurtum and staphylococcus aureus, the results showed that pass through weight caused by Pichia anomala expression
Group PR39 albumen, fungistatic effect is respectively provided with to Escherichia coli, Salmonella typhimurtum and staphylococcus aureus.By the PR39 of synthesis
After gene is connected with expression vector pCold, it is transferred in Escherichia coli, obtains restructuring PR39 albumen.By the restructuring PR39 eggs of acquisition
The white bacteriostatic experiment for Escherichia coli and Salmonella typhimurtum, the results showed that by recombinating PR39 caused by Bacillus coli expression
Albumen is similarly obtained has fungistatic effect to Escherichia coli and Salmonella typhimurtum.There is research to be carried by building PR39 eukaryotic expressions
Body pIRES2-PR39, after transfected macrophage, the energy of intracellular bacterium is killed and removed to expression antibacterial peptide PR39 macrophage
Power is remarkably reinforced, and shows that antibacterial peptide PR39 can be expressed in macrophage and be had fungistatic effect.
Antibacterial peptide has a variety of advantages compared with antibiotic, therefore turns into the study hotspot in herding disease prevention and cure at present.
Antibacterial peptide is applied to the disease prevention and cure of farming animals mainly as feed addictive or veterinary drug at present.But use artificial synthesized or table
The antibacterial peptide reached not only increases aquaculture cost, and because the activity of antibacterial peptide is easy in the production, transportation and storage process
It is affected, its antibacterial effect reduces.Therefore derived antimicrobial peptide in animal body oneself expression is made using transgenic technology, so as to improve
Its premunition, it can solve the above problems.
The content of the invention
It is an object of the invention to provide a kind of cad gene PR39 DNA murines, the transgenic mice oneself expression PR39 eggs
In vain, and to bacterium fungistatic effect is produced, to obtain the livestock and poultry of cad gene PR39 genes, especially cad gene PR39 gene pigs
Laid the foundation.
According to an aspect of the invention, there is provided a kind of cad gene PR39 DNA murines, antibacterial peptide PR39 genes
It is incorporated on No. 13 chromosome of mouse, what thus the transgenic mice can stablize PR39 genes entails offspring, and
Energy specifically expressing PR39 albumen, and there is preferably resistance effect to bacterium.
In some embodiments, antibacterial peptide PR39 genes are located on No. 13 chromosome of transgenic mice
Between GM36264 genes and GM8784 genes, what thus the transgenic mice can stablize PR39 genes entails offspring, and
Energy specifically expressing PR39 albumen, and there is preferably resistance effect to bacterium.
In some embodiments, cad gene PR39 DNA murines obtain as follows:
(1) according to PR39 gene C DS sequences, restriction enzyme site, artificial synthesized corresponding DNA sequences are increased at gene order both ends
Row;
(2) DNA sequence dna of synthesis is connected on pCMS-EGFP empty carriers, obtains antibacterial peptide PR39 expression vectors
pCMS-EGFP-PR39;
(3) functional verification is carried out to antibacterial peptide PR39 expression vectors pCMS-EGFP-PR39;
(4) it is the expression vector pCMS-EGFP-PR39 microinjections mouse fertilized egg of energy effective expression PR39 genes is male former
Core, and by the zygote transplation after injection to replace-conceive dams intrauterine, F0 is obtained for transgenic mice by gestation;
(5) F0 of acquisition is detected for transgenic mice, chooses PR39 gene expression amounts height, and integration site is single
Individual carry out follow-up study;
(6) F0 filtered out generations individual is bred with wild-type mice breeding, obtains F1 generation transgenic mice;
(7) the F1 generation transgenic mice of acquisition is detected, filtering out can stable heredity and high efficient expression PR39 gene
Individual carry out follow-up study;
(8) the F1 generation individual filtered out is bred, obtains corresponding family, and it is real to carry out antibacterium to the family
Test, obtain being highly resistant to the cad gene PR39 DNA murines of bacterium.
Thus, cad gene PR39 DNA murines are obtained by the above method, hereditary PR39 genes can be stablized, and turning
Specifically expressing PR39 albumen in DNA murine different tissues, is advantageous to the performance of the antibacterial and bacteriostasis of each tissue, plays and turn base
Because of the effect of mouse systemic tissue synthesis antibacterial.
In some embodiments, antibacterial peptide PR39 expression vectors pCMS-EGFP-PR39 gene orders are SEQ ID
NO:1, transgenic mice is obtained from there through the expression vector, there can be preferably suppression with the expression PR39 albumen of differential high efficient
Bacterium effect.
In some embodiments, expression vector pCMS-EGFP-PR39 functional verification, including expression vector is transfected
After 293 cells, carry out qPCR detections and fungistatic effect detection, it is possible thereby to judge expression vector pCMS-EGFP-PR39 whether structure
Work(is built up, and can PR39 genes correctly express in 293 cells.
In some embodiments, qPCR is detected in expression vector pCMS-EGFP-PR39 functional verification, including as follows
Step:
(1) pCMS-EGFP-PR39 expression vectors rotaring redyeing 293 cell, in fluorescence microscopy Microscopic observation green fluorescence after 24h
Protein expression situation;
(2) after 72h, cell extraction RNA is collected;
(3) qPCR detections are carried out to the RNA of extraction, qRCP response procedures are 42 DEG C of 15min, 95 DEG C of 3min.
In some embodiments, fungistatic effect detection is included such as in expression vector pCMS-EGFP-PR39 functional verification
Lower step:
(1) 293 cell culture of pCMS-EGFP-PR39 expression vectors rotaring redyeing 293 cell and blank control group untransfected
After 48h, with serum free medium culture cell 24h, culture medium is collected, by culture medium elastin laminin ferment treatment;
(2) preparation of Escherichia coli:The picking single bacterium colony in Escherichia coli plate, with 5mlLB fluid nutrient mediums, it is placed in
37 DEG C, 18-24h is cultivated in 220r/min shaking tables, 50ul bacterium solutions is drawn and expands in new 5mlLB fluid nutrient mediums and cultivates 3h,
Draw 1ml bacterium solutions and centrifuge 5min in the centrifuge that rotating speed is 2000g, outwell supernatant, be resuspended with PBS, draw 200ul in 96
In orifice plate, carry out OD values using ELIASA and detect, be from bacterial concentration:2×106CFU/ml;
(3) bacteriostatic experiment step:With 96 orifice plates, it is 2 × 10 that 25ul concentration is added per hole6CFU/ml Escherichia coli bacterium
Liquid, then add culture mediums of the 25ul after step (1) processing and mix, be positioned in 37 DEG C of incubators and cultivate 3h, added per hole
200ulLB fluid nutrient mediums, it is incubated overnight in 37 DEG C of incubators, its OD value is detected with ELIASA within second day, according to the big of OD values
It is small, to judge the fungistatic effect of pCMS-EGFP-PR39 expression vectors.
In some embodiments, F0 for transgenic mice detection, including PCR detection and PR39 gene mRNA expression amounts
Detection.
In some embodiments, the antibacterium of transgenic mice family is tested, comprised the following steps:
(1) it is 6x10 with concentration to the transgenic lines and nontransgenic mice of acquisition5CFU/, 3x106CFU/,
6x106CFU/, 6x107The actinobacillus pleuropneumoniaes of CFU/ only are by being injected intraperitoneally transgenic mice group and non-transgenic
Mouse group;
(2) mouse treated to step (1), is cultivated, in different time node, the death rate of mouse is united
Meter analysis.
In some embodiments, actinobacillus pleuropneumoniae concentration is in the detection of transgenic mice antibacterial
3x106CFU/ is only.
The cad gene PR39 DNA murines obtained through the above way, there is beneficial effect:
1st, the PR39 gene integrations of cad gene PR39 DNA murines are located on No. 13 chromosome of mouse
Between GM36264 genes and GM8784 genes, what can be stablized entail offspring, and can specifically expressing PR39 albumen, have compared with
Good fungistatic effect.
2nd, cad gene PR39 DNA murines show that PR39 genes can express in different tissues of mice, and can send out
Wave bacteriostasis.
3rd, acquisition being provided for the domestic animal of other cad genes PR39 genes of cad gene PR39 DNA murines
Research foundation has been established, resolving ideas is provided to solve the use of antibiotic during cattle breeding.
Brief description of the drawings
Fig. 1 is the digestion qualification result figure of expression vector pCMS-EGFP-PR39 in embodiment 1:Wherein 1 is plasmid pCMS-
EGFP-PR39,2 be BamHI and XhoI double digestions pCMS-EGFP-PR39, and 3 be DNALadder;
Fig. 2 is the sequencing result figure of expression vector pCMS-EGFP-PR39 in embodiment 1;
Fig. 3 is the fluoroscopic examination result figure after expression vector pCMS-EGFP-PR39 rotaring redyeing 293 cells 24h in embodiment 2;
Fig. 4 is PR39 gene mRNA relative expressions after expression vector pCMS-EGFP-PR39 rotaring redyeing 293 cells in embodiment 2
Measure result figure:Wherein ND is that PR39 expression is not detected by mRNA level in-site, (1) and (2) culture that to be respectively two different
Hole;
PCR testing result figures of the Fig. 5 for F0 in embodiment 3 for transgenic mice:Wherein P is positive control, and Neg is feminine gender
Control, W are water, and 426-433 is to turn PR39 DNA murines numbering in F0 generations, and 165 be PR39 genetic fragment sizes, and 110 be GAPDH pieces
Duan great little;
Fig. 6 is transgenic mice EGFP gene copy number results figure in embodiment 3;
Fig. 7 is transgenic mice PR39 gene mRNA relative expression quantity result figures in embodiment 3:Wherein 426-433 is to turn
DNA murine is numbered, and is organized as transgenic mice tail in figure used in quantitative PCR, and ND is to be not detected by PR39's in mRNA level in-site
Expression;
Fig. 8 is the PCR testing result figures of F1 generation transgenic mice in embodiment 4:Wherein M is 500bp marker, numbering
It is respectively F1 generation birth mouse for 1-11, P is positive control, and W is water;
Fig. 9 is that F1-9 transgenic mices respectively organize PR39 gene mRNA relative expression quantity result figures in embodiment 4;
Figure 10 is F1-9 transgenic mice portion of tissue PR39 protein concentration expression of results figures in embodiment 4;
Figure 11 is F1-9 transgenic mice integration site analysis result figures in embodiment 5;
Figure 12 is that F1-9 transgenic mices family attacks death rate testing result after poison with nontransgenic mice in embodiment 6
Figure.
Embodiment
Invention is described in further detail below in conjunction with the accompanying drawings.
Unless otherwise specified, the reagent used in following examples derives from commercially available.
Embodiment 1:Antibacterial peptide PR39 expression vectors pCMS-EGFP-PR39 structure
(1) synthesis of antibacterial peptide PR39 genes
PR-39 gene C DS region sequences (the GenBank accession number announced according to NCBI::L23825.1),
The artificial synthesized of gene is carried out, and XhoI and NotI restriction enzyme sites are provided with gene order both ends.
(2) carrier for expression of eukaryon pCMS-EGFP digestion
1) carrier for expression of eukaryon pCMS-EGFP linearisation
Using two enzyme digestion reporter gene EGFP of Xhol, Notl carrier for expression of eukaryon pCMS-EGFP (purchased in market),
Make vector linearization, while there is cohesive terminus,cohesive termini, digestion system is with reference to Fermentas companies restriction enzyme XhoI and NotI
Specification, as shown in table 1.
The double digestion system of the carrier pCMS-EGFP sequences of table 1
Above-mentioned reaction system is fully mixed, 37 DEG C of digestion 15-30min, with reference to the purification kit of Transgen companies
EasyTMPCRPurification specifications carry out purifying recovery to digestion products.
2) digestion of PR39 genes
The double digestion of two enzymes of Xhol, Notl is carried out to the PR39 gene DNA fragments of synthesis, makes DNA fragmentation that there is stickiness
End, digestion system reference Fermentas companies restriction enzyme XhoI and NotI specification, as shown in table 2:
The double digestion system of the PR39 gene DNA sequences of table 2
Above-mentioned reaction system is fully mixed, 37 DEG C of digestion 15-30min, with reference to the purification kit of Transgen companies
EasyTM PCR Purification specifications carry out purifying recovery to digestion products.
(3) after digestion carrier pCMS-EGFP and-PR39 connection and conversion
The digestion products of above-mentioned recovery are attached by system in table 3, linked system is with reference to TaKaRa company DNA
Ligation Kit Ver.2.0 connections kit illustrates that concrete operations are as follows:
The linked system of the PR39 genes of table 3 and carrier pCMS-EGFP
The competent cell DH5 α of preservation are melted in ice, take 30 μ L competent cells gently to be mixed with the μ L of connection product 1
It is even, ice bath 30min, 42 DEG C of heat shock 45s, it is quickly transferred to cool down 2min in ice bath, adds the LB Liquid Cultures of 1mL antibiotic-frees
Base, 37 DEG C are placed in, 1h is cultivated in 220r/min shaking tables, take 200 μ L bacterium solutions to be coated in LA flat boards, 37 DEG C of overnight incubations.
(4) PCR and sequencing identification
The picking single bacterium colony in the flat board of above-mentioned culture, it is suspended from 10 μ L aqua sterilisas, takes 2 μ L to carry out bacterium colony as template
PCR, remaining 4 DEG C preservations.Positive bacterium solution PCR identification primers (being shown in Table 4) are designed, directly take bacterium solution to enter performing PCR identification as template,
Reaction system and program are carried out with reference to GenestarMix Kit specifications, and PCR primer is examined with 1% agarose gel electrophoresis
Survey.
The positive bacterium solution PCR identifications design of primers of table 4
The bacterium solution of test positive is re-seeded into LB culture mediums of the 5mL containing Amp, 37 DEG C of 220r/min shaking table cultures
12-16h, operated with reference to OMEGA companies E.Z.N.A.TM Plasmid Mini Kit II kit specifications.
The plasmid for taking 1 μ L to extract, the restriction enzyme site XhoI and NotI that both sides are inserted from exogenous sequences carry out double digestion mirror
It is fixed, electrophoresis detection digestion result, the results showed that plasmid, which is cut open, is divided into 4683bp and 1382bp two parts, with expected size phase
Symbol, it was demonstrated that carrier pCMS-EGFP-PR39 structures are qualified, and testing result refers to accompanying drawing 1.
When digestion result with expection be consistent, select 2-3 clone be sent to lifetechnologies companies progress positive and negative two
Individual direction sequencing, sequencing result and aim sequence is compared, testing result such as accompanying drawing 2, sequencing result is correct, enters one
Step shows that expression vector pCMS-EGFP-PR39 structures are qualified, and gene order number is SEQ ID NO:1.
Embodiment 2:Antibacterial peptide PR39 expression vectors pCMS-EGFP-PR39 functional verification
(1) cell of plasmid transfection 293, and carry out fluorescence microscope detection
Correct transgene carrier pCMS-EGFP-PR39 and control group carrier pCMS-EGFP bacterium solutions will be sequenced in 37 DEG C
Expand culture 12-16h in 220r/min shaking tables, collect bacterium solution and carry out endotoxin plasmid extraction, plasmid extraction process reference
OMEGA companies E.Z.N.A.TM EndoFree Plasmid Mini Kit II kit specifications are operated.Take 1 μ L matter
Grain DNA carries out quality testing using nucleic acid concentration instrument, and DNA of 260/280 value between 1.8~2.0 can be used for cell
Transfection experiment.
Passage to 6 orifice plates is cultivated, when cell grow to degree of converging be 80% when, the plasmid that will build
PCMS-EGFP-PR39 and carrier pCMS-EGFP is in liposome-mediated lower rotaring redyeing 293 cell.Experimental procedure is with reference to life
Technologies companies Lipofectamine TM LTX and PLUSTM Reagent kit specifications are carried out.
When observation cell confluency degree reaches 80%, liposome-mediated transfection can be carried out.
4 kinds of interference plasmids are diluted to 500 μIn basic culture solution, mix.Matter are disturbed by with 4 kinds
Grain volume ratio 1:1 ratio adds LipofectamineTMPLUS Reagent (gently being shaken up using preceding) arrive above-mentioned mixed solution
In, gently shake up, be incubated at room temperature 5min.By LipofectamineTMLTX (gently being shaken up using preceding) is added directly into dilute
In the 4 kinds of interference plasmid solution released, gently shake up, be incubated at room temperature 30min.
In the process, after washing the cell of mouse 293 with serum-free medium, fresh 10% hyclone training is added
Nutrient solution.
DNA- liposome mixed liquors are added dropwise in each hole, cell is put back into 37 DEG C of 5%CO2 after gently shaking up and satisfied
Continue to cultivate with the incubator of humidity.
After 4-6h, renew the fresh nutrient solution containing 10% hyclone.After cultivating 24h, seen under fluorescence microscope
Examine.As a result as shown in Figure 3:Display eukaryon expression plasmid pCMS-EGFP-PR39 and pCMS-EGFP empty carrier can detect
To specificity fluorescent, illustrate two plasmid Successful transfections into 293 cells, and transfection efficiency is up to more than 60%.
(2) after the cell of plasmid transfection 293 PR39 genes the detection of expression in mRNA level in-site
It is rough to judge respectively with the fluorescence power situation in each hole of fluorescence microscope after the cell 24h of plasmid transfection 293
The transfection efficiency of plasmid.72h collects cell, and cell RNA is extracted using conventional method, by the RNA of extracting, reference TAKARA companies
Reverse transcription reagent box specification carries out reverse transcription, and RT-PCR relative quantifications are carried out with the cDNA after reverse transcription.Reverse transcription step is such as
Under, genomic DNA removes system such as table 5, and reverse transcription reaction system is as shown in table 6.PR39 genes, EGFP gene and reference gene
Primer, it is as shown in table 8 that primer sequence is shown in Table 7, RT-PCR reaction systems.
Cell RNA extraction steps are as follows:
1) RNA extraction steps
Cell is collected, cell is blown and beaten after addition 1mLTRIzol repeatedly and is stored at room temperature 5min 200 μ L chloroforms of addition, vibration is mixed
It is even, 5min12000g is stored at room temperature, supernatant is transferred to the body such as addition and supernatant in new centrifuge tube by 4 DEG C of centrifugation 15min
Long-pending isopropanol, 10min, 12000g, 4 DEG C of centrifugation 10min are stored at room temperature, abandoning supernatant, the 75% of 1mL are added into precipitation
Ethanol 12000g, 4 DEG C of centrifugation 5min abandoning supernatants, 10min is dried at room temperature and adds 36 μ LDEPC processing water, dissolves RNA.
2) reverse transcription step
1. organize RNA digestion:Purpose is in order to remove the genomic DNA in RNA, to prevent influenceing RT-PCR results.Make
It is as shown in table 5 with the gDNAEraser that reagent is Takara companies, reaction system.
The genomic DNA of table 5 removes system
After sample has added mixing, 2min is incubated in 42 DEG C, removes genomic DNA;Then in 4 DEG C of preservations.
2. mixed liquor is placed in the mixing for carrying out reaction system according to table 6 on ice, Suo Youcao by above-mentioned reaction immediately after terminating
Work is carried out on ice.
The reverse transcription reaction system of table 6
Above-mentioned system is mixed, 15min is incubated in 37 DEG C, then heats 5seconds terminating reactions in 85 DEG C, synthesis
CDNA is placed in -20 DEG C of preservations.
It is 3. enterprising in PCR instrument according to 42 DEG C of 15min of response procedures, 95 DEG C of 3min after above-mentioned reactive component is fully mixed
Row reaction.React -20 DEG C of preservations of reverse transcription product or progress quantitative RT-PCR detection after terminating.The testing result such as institute of accompanying drawing 4
Show, 293 cell lines of transfection pCMS-EGFP-PR39 plasmids have the expression of PR39 genes, and (pCMS-EGFP plasmids turn NC control groups
Dye) and blank control group (no processing) be not detected by the expression of PR39 genes.
The detection primer of the PR39 genes of table 7, EGFP gene and reference gene (GAPDH)
The RT-PCR reaction systems of table 8
(3) detection after the cell of plasmid transfection 293 to Escherichia coli inhibition
With serum free medium culture cell after 293 cell 48h of the cell of plasmid transfection 293 and blank control group untransfected
24h, culture medium is collected, by culture medium elastin laminin ferment treatment, the transgene carrier pCMS- after elastin laminin ferment treatment
EGFP-PR39 can obtain the PR39 of maturation.Elastoser application method reference SIGMA companies, product article No. are:E-8140
Operation instruction carries out digestion and (300ul physiology salt aqueous fusions is used, with 1:10 system carries out digestion).
The preparation of Escherichia coli, the picking single bacterium colony in Escherichia coli plate, with 5mlLB fluid nutrient mediums, it is placed in 37
DEG C, 18-24h is cultivated in 220r/min shaking tables, 50ul bacterium solutions is drawn and expands culture 3h in new 5ml LB fluid nutrient mediums, inhale
Take 1ml bacterium solutions to centrifuge 5min in the centrifuge that rotating speed is 2000g, outwell supernatant, be resuspended with PBS, draw 200ul in 96 holes
In plate, carry out OD values using ELIASA and detect, with reference to OD value corresponding concentration formula:Bacterial concentration (CFU/ml)=OD (620nm)
X2.5x108 calculates its concentration, is from bacterial concentration:2×106CFU/ml。
Bacteriostatic experiment step, with 96 orifice plates, 25ul concentration is added per hole is:2×106CFU/ml Escherichia coli bacteria liquid,
Then 25ul culture mediums are added to mix, is positioned in 37 DEG C of incubators and cultivates 3h, the addition 200ulLB fluid nutrient mediums per hole, 37
It is incubated overnight in DEG C incubator, detects its OD value with ELIASA within second day.
Testing result is as shown in table 8, the results showed that the cell training collected after the cell of pCMS-EGFP-PR39 plasmid transfections 293
The bacterial concentration value for supporting the Escherichia coli of base processing is substantially less than the cell culture medium collected after pCMS-EGFP rotaring redyeing 293 cells
The bacterial concentration value of the Escherichia coli of processing, illustrate that the PR39 albumen that secretion is expressed from HEK293 cells can significantly inhibit large intestine
The growth of bacillus, expression vector pCMS-EGFP-PR39 are successfully constructed.
Inhibitory action of the cell conditioned medium to Escherichia coli after the cell of 8 plasmid transfection of table 293
Embodiment 3:In F0 generations, turn the preparation and identification of PR39 DNA murines
By the transgene expression vector pCMS-EGFP-PR39 of linearisation, after empirical tests are qualified, using pronuclear microinjection
Method prepare turn PR39 DNA murines.
(1) in F0 generations, turn the PCR identifications of PR39 DNA murines
Clip birth mouse tail is organized on a small quantity, extracts mouse tail tissue DNA, operating procedure is according to OMEGA companies DNA
Extraction agent box specification is carried out.
PCR is detected:The both ends of PR39 genes insertion position separately design primer in carrier sequence, using clone with plasmid as
Positive control, foreign gene is expanded, while the internal control primer GAPDH for designing mouse comes the integrality of validating DNA, PCR reactants
System is shown in Table 9.As a result see accompanying drawing 5, the results showed that have 8 mouse for transgenic mice (i.e. F0 for mouse, be respectively labeled as 426,
427th, 428,429,430,431,432 and No. 433), wherein 6 transgenosis public affairs mouse (marked as:426、427、428、429、430、
431), 2 transgenosis dams (marked as:432 and 433).
The PCR reaction systems of table 9
(2) in F0 generations, turn the detection of PR39 DNA murine EGFP luciferase expressions
Using EGFP albumen blue light excite it is lower it is observed that green fluorescence come the preliminary mouse for judging to be born whether be
Transgenic mice.Taken pictures respectively under white light background and blue light background, observe the expression of green fluorescence.Camera is adjusted to light
Mode of priority is enclosed, parameter is respectively:White light aperture F2.8, ISO100;Blue light aperture F2.8, ISO4000.
As a result see accompanying drawing 6, the results showed that the EGFP gene copy number of 8 positive transgenic mices of PCR detections 1-8 it
Between, wherein having the copy numbers of 4 transgenic mices (be respectively 426,429,430 and 431) close to single copy.Because EGFP is marked
Remember gene and target gene PR39 amalgamation and expressions, thus, thus EGFP gene is also single copy if single copy, target gene.
(3) in F0 generations, turn the qPCR detections of PR39 DNA murines
To detect PR39 gene mRNA expression situations, using the mouse tail tissue of extracting, pass through real-time fluorescence quantitative PCR
Method, the detection of PR39 gene mRNAs relative expression quantity is carried out, testing result is as shown in Figure 7.In 8 transgenic mices only
426th, detect that PR39mRNA is expressed in the tail tissue of 427 and 430 3 transgenic mices, and transgenic mice 427
PR39mRNA relative expression quantity highests.
Embodiment 4:F1 generation turns the preparation identification and detection of PR39 DNA murines
It is high for PR39mRNA expression quantity in mouse, is selected in F0 according to testing result, and the F0 generations 427 that integration site is single
With 430 mouse with carrying out breeding breeding with kind wild-type mice, F1 generation mouse is obtained, and F1 generation mouse is identified.
(1) F1 generation turns the PCR identifications of PR39 DNA murines
Clip birth mouse tail is organized on a small quantity, extracts mouse tail tissue DNA, operating procedure is according to kit specification
Carry out.
PCR is detected:The both ends of PR39 genes insertion position separately design primer in carrier sequence, using clone with plasmid as
Positive control, foreign gene is expanded, while the internal control primer GAPDH for designing mouse carrys out the integrality of validating DNA.As a result such as accompanying drawing
Shown in 8, the results showed that have 8 F1 generation transgenic mices can stablize expression PR39 genes, respectively F1-2, F1-3, F1-5,
F1-7, F1-8, F1-9, F1-10, F1-11, PR39 gene expression amount highests in F1-9 individuals can be seen that by accompanying drawing 8, thus select
Select F1-9 individuals and carry out follow-up study.
(2) detection of F1-9 transgenic mices different tissues PR39mRNA relative expression quantities
The primer of PR39 genes can be expanded according to PR39 genes design in plasmid, detection plasmid turns PR39 genes in difference
Relative expression's situation in mouse.Select the F1-9 transgenic mices that can stablize expression PR39 genes in F1 generation individual, extracting group
Knit RNA and PR39 gene mRNA expression amount situations in tissue are detected by real-time fluorescence quantitative PCR.As a result as shown in Figure 9, F1-9
Totally 7 tissues can express PR39 gene mRNAs for the transgenic mice heart, liver, spleen, lung, kidney, muscle, lymph node.
(3) detection of the ELISA method to F1-9 transgenic mice PR39 protein concentrations is used
1) antigenic content detects:
Collection F1-9 turns PR39 DNA murine blood, is collected with EDTA anticoagulant tubes, blood plasma is obtained, according to EIAab companies
The content of PR39 antigens in ELISAKitforpigPR39 kits operating procedure detection blood.F1 is detected using identical method
In generation, turns the content of PR39 antigens in the tissue such as the PR39 DNA murines heart, liver, spleen, lung, kidney, muscle.
2) ELISA operating procedures:
Before detection, each reagent all should be balanced to room temperature (reagent directly can not dissolve at 37 DEG C);Reagent or sample dilution
When, it is both needed to mix, avoids bubbling as far as possible during mixing.Sample size should be predicted before experiment, as sample concentration it is too high when, tackle sample
Be diluted so that after dilution samples met kit detection range, multiplied by with corresponding extension rate during calculating.
1. it is loaded:Blank well, gauge orifice, testing sample hole are set respectively.In addition to blank well, remaining hole add respectively standard liquid or
Testing sample 100ul, is gently mixed, and ELISA Plate is plus lid, 37 DEG C of incubation 120min.(it is loaded and sample is added on ELISA Plate bottom,
Bubble has been careful not to, has not touched hole wall as far as possible)
2. discarding liquid, dry, without washing.Do not have directly hole to add detection solution A working solution 100ul (small using first half
When interior preparation), gently rock mixing, ELISA Plate adds overlay film, 37 DEG C of incubation 60min.
3. discarding liquid, dry, board-washing 3 times.Immersion 1-2min every time, about 400ul/ holes, dry (gently patting dry).
4. adding detection liquid B working solution 100ul per hole, ELISA Plate adds overlay film, 37 DEG C of incubation 60min, board-washing 5 times.
5. substrate solution 90ul, 37 DEG C of preceding 3-4 for being incubated 15-30min, now naked eyes visual standard product are added per plate successively
There are obvious gradient blueness, rear 3-4 gradient pores unobvious in hole.
6. stop bath 50ul is added per plate successively, terminating reaction (now blueness switchs to yellow immediately).
7. measure the optical density (OD values) in each hole successively in 450nm wavelength with enzyme-linked instrument.
8. liquid A and detection liquid B are detected to detect liquid:Liquid=1 after dilution:100 dilution proportion
It is 9. same according to concentration value corresponding to the extension rate provided on standard curve difference extension rate OD values and specification
When use CurveExpert1.4 analysis softwares.
ELISA testing results as shown in Figure 10, antibacterial peptide are detected in F1-9 transgenic mices kidney, spleen and blood plasma
PR39 is present, wherein PR39 protein concentration values are in nephridial tissue:1430pg/mg;PR39 protein concentration values are in tissue spleen:
835pg/mg;PR39 protein concentration values are in blood plasma:58446pg/ml.
Embodiment 5:Inverse PCR determines integration site of the antibacterial peptide PR39 genes in F1-9 transgenic mice individuals
DNA using F1-9 transgenic mices individual is template, and design direction PCR draws based on antibacterial peptide PR39 genes
Thing, inverse PCR is carried out, and PCR primer is sequenced, sequencing result is compared with pig whole genome sequence, as a result such as
Shown in accompanying drawing 11, antibacterial peptide gene is incorporated on No. 13 chromosome of transgenic mice, positioned at GM36264 genes and GM8784
Between two functional genes of gene, the expression of the F1-9 transgenic mice individual normal genes, while antibacterial peptide are not interfered with
PR39 gene integrations have higher expression effect in the site.
Embodiment 6:F1-9 transgenic mice family antibacterium (APP) infection ability is analyzed
Bred to obtaining F1-9 transgenic mices, obtain F1-9 transgenic mice familys, and to the transgenic mice
The analysis of anti-actinobacillus pleuropneumoniae (App) infection ability is carried out, it is specific as follows:
It is 6x10 with toxic agent amount is attacked6The actinobacillus pleuropneumoniaes of CFU/ only are injected simultaneously by way of intraperitoneal injection
Transgenic mice 20, nontransgenic mice 20.Attack 5h mouse after poison start to occur it is dead, to attacking 17h dead mouses after poison
Rate is not further added by.
As a result see accompanying drawing 12, show that 5h mouse start death occur after attacking poison, are raising always from the death rate between 5-17h.
The non-transgenic group death rate reaches 64.7% wherein in 9h, is extremely significantly significantly higher than the 33.3% of transgenosis group;In 13h
The non-transgenic group death rate reaches 82.4%, is significantly higher than the 66.7% of transgenosis group.This shows antibacterial in transgenic mice body
Peptide PR39 may strengthen the antibacterial ability of mouse, delay mouse diing time, reduce mouse death rate.
In other embodiments, the toxic agent amount of attacking of actinobacillus pleuropneumoniae (App) can also be 6x105CFU/,
3x106CFU/, 6x107CFU/ isoconcentration.
Above-described is only some embodiments of the present invention.For the person of ordinary skill of the art, not
On the premise of departing from the invention design, various modifications and improvements can be made, these belong to the protection domain of invention.
SEQUENCE LISTING
<110>Agricultural University Of South China
<120>A kind of cad gene PR39 DNA murines
<130> 2017
<160> 1
<170> PatentIn version 3.3
<210> 1
<211> 6065
<212> DNA
<213>Artificial sequence
<400> 1
tcaatattgg ccattagcca tattattcat tggttatata gcataaatca atattggcta 60
ttggccattg catacgttgt atctatatca taatatgtac atttatattg gctcatgtcc 120
aatatgaccg ccatgttggc attgattatt gactagttat taatagtaat caattacggg 180
gtcattagtt catagcccat atatggagtt ccgcgttaca taacttacgg taaatggccc 240
gcctggctga ccgcccaacg acccccgccc attgacgtca ataatgacgt atgttcccat 300
agtaacgcca atagggactt tccattgacg tcaatgggtg gagtatttac ggtaaactgc 360
ccacttggca gtacatcaag tgtatcatat gccaagtccg ccccctattg acgtcaatga 420
cggtaaatgg cccgcctggc attatgccca gtacatgacc ttacgggact ttcctacttg 480
gcagtacatc tacgtattag tcatcgctat taccatggtg atgcggtttt ggcagtacac 540
caatgggcgt ggatagcggt ttgactcacg gggatttcca agtctccacc ccattgacgt 600
caatgggagt ttgttttggc accaaaatca acgggacttt ccaaaatgtc gtaacaactg 660
cgatcgcccg ccccgttgac gcaaatgggc ggtaggcgtg tacggtggga ggtctatata 720
agcagagctc gtttagtgaa ccgtcagatc actagaagct ttattgcggt agtttatcac 780
agttaaattg ctaacgcagt cagtgcttct gacacaacag tctcgaactt aagctgcagt 840
gactctctta aggtagcctt gcagaagttg gtcgtgaggc actgggcagg taagtatcaa 900
ggttacaaga caggtttaag gagaccaata gaaactgggc ttgtcgagac agagaagact 960
cttgcgtttc tgataggcac ctattggtct tactgacatc cactttgcct ttctctccac 1020
aggtgtccac tcccagttca attacagctc ttaaggctag agtacttaat acgactcact 1080
ataggctagc ctcgagaggc ctgccaccat ggagacccag agggccagcc tgtgcctggg 1140
gcgctggtca ctgtggcttc tgctgctggg actcgtggtg ccctcggcca gcacccaggc 1200
cctcagctac agggaggccg tgcttcgtgc tgtggatcgc ctcaacgagc agtcctcgga 1260
agctaatctc taccgcctcc tggagctgga ccaaccgccc aaggccgacg aggacccggg 1320
caccccaaaa cctgtgagct tcacggtgaa ggagactgtg tgtcccaggc cgacccagcg 1380
gcccccggag ctgtgtgact tcaaggagaa cgggcgagtg aagcagtgtg tggggacagt 1440
caccttgaac ccatccaatg acccactgga catctcctgt aatgagattc agagtgtcag 1500
gagacgtccc cgacccccat atttgccaag gccaaggcca cctccgtttt tcccaccaag 1560
gctcccacca aggatcccac cagggttccc accaaggttc ccaccacggt tccccggaaa 1620
acggcaccac caccaccacc actgaggcgc gccgcggccg cttcccttta gtgagggtta 1680
atgcttcgca gacatgataa gatacattga tgagtttgga caaaccacaa ctagaatgca 1740
gtgaaaaaaa tgctttattt gtgaaatttg tgatgctatt gctttatttg taaccattat 1800
aagctgcaat aaacaagtta acaacaacaa ttgcattcat tttatgtttc aggttcaggg 1860
ggagatgtgg gaggtttttt aaagcaagta aaacctctac aaatgtggta aaatccgata 1920
aggatcgatc cgggctggcg taatagcgaa gaggcccgca ccgatcgccc ttcccaacag 1980
ttgcgcagcc tgaatggcga atggacgcgc cctgtagcgg cgcattaagc gcggcgggtg 2040
tggtggttac gcgcagcgtg accgctacac ttgccagcgc cctagcgccc gctcctttcg 2100
ctttcttccc ttcctttctc gccacgttcg ccggctttcc ccgtcaagct ctaaatcggg 2160
ggctcccttt agggttccga tttagagctt tacggcacct cgaccgcaaa aaacttgatt 2220
tgggtgatgg ttcacgtagt gggccatcgc cctgatagac ggtttttcgc cctttgacgt 2280
tggagtccac gttctttaat agtggactct tgttccaaac tggaacaaca ctcaacccta 2340
tctcggtcta ttcttttgat ttataaggga ttttgccgat ttcggcctat tggttaaaaa 2400
atgagctgat ttaacaaata tttaacgcga attttaacaa aatattaacg tttacaattt 2460
cgcctgatgc ggtattttct ccttacgcat ctgtgcggta tttcacaccg catacgcgga 2520
tctgcgcagc accatggcct gaaataacct ctgaaagagg aacttggtta ggtaccttct 2580
gaggcggaaa gaaccagctg tggaatgtgt gtcagttagg gtgtggaaag tccccaggct 2640
ccccagcagg cagaagtatg caaagcatgc atctcaatta gtcagcaacc aggtgtggaa 2700
agtccccagg ctccccagca ggcagaagta tgcaaagcat gcatctcaat tagtcagcaa 2760
ccatagtccc gcccctaact ccgcccatcc cgcccctaac tccgcccagt tccgcccatt 2820
ctccgcccca tggctgacta atttttttta tttatgcaga ggccgaggcc gcctcggcct 2880
ctgagctatt ccagaagtag tgaggaggct tttttggagg cctaggcttt tgcaaaaagc 2940
ttgccacaac ccgggatcca ccggtcgcca ccatggtgag caagggcgag gagctgttca 3000
ccggggtggt gcccatcctg gtcgagctgg acggcgacgt aaacggccac aagttcagcg 3060
tgtccggcga gggcgagggc gatgccacct acggcaagct gaccctgaag ttcatctgca 3120
ccaccggcaa gctgcccgtg ccctggccca ccctcgtgac caccctgacc tacggcgtgc 3180
agtgcttcag ccgctacccc gaccacatga agcagcacga cttcttcaag tccgccatgc 3240
ccgaaggcta cgtccaggag cgcaccatct tcttcaagga cgacggcaac tacaagaccc 3300
gcgccgaggt gaagttcgag ggcgacaccc tggtgaaccg catcgagctg aagggcatcg 3360
acttcaagga ggacggcaac atcctggggc acaagctgga gtacaactac aacagccaca 3420
acgtctatat catggccgac aagcagaaga acggcatcaa ggtgaacttc aagatccgcc 3480
acaacatcga ggacggcagc gtgcagctcg ccgaccacta ccagcagaac acccccatcg 3540
gcgacggccc cgtgctgctg cccgacaacc actacctgag cacccagtcc gccctgagca 3600
aagaccccaa cgagaagcgc gatcacatgg tcctgctgga gttcgtgacc gccgccggga 3660
tcactctcgg catggacgag ctgtacaagt aaagcggccc tagagctcgc tgatcagcct 3720
cgactgtgcc ttctagttgc cagccatctg ttgtttgccc ctcccccgtg ccttccttga 3780
ccctggaagg tgccactccc actgtccttt cctaataaaa tgaggaaatt gcatcgcatt 3840
gtctgagtag gtgtcattct attctggggg gtggggtggg gcaggacagc aagggggagg 3900
attgggaaga caatagcagg catgctgggg atgcggtggg ctctatggct tctgaggcgg 3960
aaagaaccag ctggggcaga tccgcgtatg gtgcactctc agtacaatct gctctgatgc 4020
cgcatagtta agccagcccc gacacccgcc aacacccgct gacgcgccct gacgggcttg 4080
tctgctcccg gcatccgctt acagacaagc tgtgaccgtc tccgggagct gcatgtgtca 4140
gaggttttca ccgtcatcac cgaaacgcgc gagacgaaag ggcctcgtga tacgcctatt 4200
tttataggtt aatgtcatga taataatggt ttcttagacg tcaggtggca cttttcgggg 4260
aaatgtgcgc ggaaccccta tttgtttatt tttctaaata cattcaaata tgtatccgct 4320
catgagacaa taaccctgat aaatgcttca ataatattga aaaaggaaga gtatgagtat 4380
tcaacatttc cgtgtcgccc ttattccctt ttttgcggca ttttgccttc ctgtttttgc 4440
tcacccagaa acgctggtga aagtaaaaga tgctgaagat cagttgggtg cacgagtggg 4500
ttacatcgaa ctggatctca acagcggtaa gatccttgag agttttcgcc ccgaagaacg 4560
ttttccaatg atgagcactt ttaaagttct gctatgtggc gcggtattat cccgtattga 4620
cgccgggcaa gagcaactcg gtcgccgcat acactattct cagaatgact tggttgagta 4680
ctcaccagtc acagaaaagc atcttacgga tggcatgaca gtaagagaat tatgcagtgc 4740
tgccataacc atgagtgata acactgcggc caacttactt ctgacaacga tcggaggacc 4800
gaaggagcta accgcttttt tgcacaacat gggggatcat gtaactcgcc ttgatcgttg 4860
ggaaccggag ctgaatgaag ccataccaaa cgacgagcgt gacaccacga tgcctgtagc 4920
aatggcaaca acgttgcgca aactattaac tggcgaacta cttactctag cttcccggca 4980
acaattaata gactggatgg aggcggataa agttgcagga ccacttctgc gctcggccct 5040
tccggctggc tggtttattg ctgataaatc tggagccggt gagcgtgggt ctcgcggtat 5100
cattgcagca ctggggccag atggtaagcc ctcccgtatc gtagttatct acacgacggg 5160
gagtcaggca actatggatg aacgaaatag acagatcgct gagataggtg cctcactgat 5220
taagcattgg taactgtcag accaagttta ctcatatata ctttagattg atttaaaact 5280
tcatttttaa tttaaaagga tctaggtgaa gatccttttt gataatctca tgaccaaaat 5340
cccttaacgt gagttttcgt tccactgagc gtcagacccc gtagaaaaga tcaaaggatc 5400
ttcttgagat cctttttttc tgcgcgtaat ctgctgcttg caaacaaaaa aaccaccgct 5460
accagcggtg gtttgtttgc cggatcaaga gctaccaact ctttttccga aggtaactgg 5520
cttcagcaga gcgcagatac caaatactgt ccttctagtg tagccgtagt taggccacca 5580
cttcaagaac tctgtagcac cgcctacata cctcgctctg ctaatcctgt taccagtggc 5640
tgctgccagt ggcgataagt cgtgtcttac cgggttggac tcaagacgat agttaccgga 5700
taaggcgcag cggtcgggct gaacgggggg ttcgtgcaca cagcccagct tggagcgaac 5760
gacctacacc gaactgagat acctacagcg tgagctatga gaaagcgcca cgcttcccga 5820
agggagaaag gcggacaggt atccggtaag cggcagggtc ggaacaggag agcgcacgag 5880
ggagcttcca gggggaaacg cctggtatct ttatagtcct gtcgggtttc gccacctctg 5940
acttgagcgt cgatttttgt gatgctcgtc aggggggcgg agcctatgga aaaacgccag 6000
caacgcggcc tttttacggt tcctggcctt ttgctggcct tttgctcaca tggctcgaca 6060
gatct 6065
Claims (10)
1. a kind of cad gene PR39 DNA murines, it is characterised in that the antibacterial peptide PR39 gene integrations turn antibacterial described
On No. 13 chromosome of peptide PR39 DNA murines.
2. cad gene PR39 DNA murines according to claim 1, it is characterised in that the antibacterial peptide PR39 gene positions
Between the GM36264 genes and GM8784 genes on the 13rd chromosome of transgenic mice.
3. cad gene PR39 DNA murines according to claim 2, it is characterised in that described cad gene PR39 bases
Because mouse obtains as follows:
(1) according to PR39 gene C DS sequences, restriction enzyme site, artificial synthesized corresponding DNA sequence dna are increased at gene order both ends;
(2) DNA sequence dna of synthesis is connected on pCMS-EGFP empty carriers, obtains antibacterial peptide PR39 expression vectors pCMS-
EGFP-PR39;
(3) functional verification is carried out to antibacterial peptide PR39 expression vectors pCMS-EGFP-PR39;
(4) by can effective expression PR39 genes expression vector pCMS-EGFP-PR39 microinjection mouse fertilized egg male pronucleus,
And by the zygote transplation after injection to replace-conceive dams intrauterine, F0 is obtained for transgenic mice by gestation;
(5) F0 of acquisition is detected for transgenic mice, chooses PR39 gene expression amounts height, and that integration site is single
Body carries out follow-up study;
(6) F0 filtered out generations individual is bred with wild-type mice breeding, obtains F1 generation transgenic mice;
(7) the F1 generation transgenic mice of acquisition is detected, filtering out can be stable hereditary and high efficient expression PR39 genes
Body carries out integration site analysis, and is used for follow-up study;
(8) the F1 generation individual filtered out is bred, obtains corresponding family, and antibacterium experiment is carried out to the family, obtained
To the cad gene PR39 DNA murines for being highly resistant to bacterium.
4. cad gene PR39 DNA murines according to claim 3, it is characterised in that the antibacterial peptide PR39 gene tables
It is SEQ ID NO up to carrier pCMS-EGFP-PR39 gene orders:1.
5. cad gene PR39 DNA murines according to claim 3, it is characterised in that the step (3) is included table
Up to after carrier rotaring redyeing 293 cell, qPCR detections and fungistatic effect detection are carried out.
6. cad gene PR39 DNA murines according to claim 5, it is characterised in that described qPCR detections, including
Following steps:
(1) pCMS-EGFP-PR39 expression vectors rotaring redyeing 293 cell, in fluorescence microscopy Microscopic observation green fluorescent protein after 24h
Expression;
(2) after 72h, cell extraction RNA is collected;
(3) qPCR detections are carried out to the RNA of extraction, qRCP response procedures are 42 DEG C of 15min, 95 DEG C of 3min.
7. cad gene PR39 DNA murines according to claim 5, it is characterised in that described fungistatic effect detection bag
Include following steps:
(1) after 293 cell culture 48h of pCMS-EGFP-PR39 expression vectors rotaring redyeing 293 cell and blank control group untransfected,
With serum free medium culture cell 24h, culture medium is collected, by culture medium elastin laminin ferment treatment;
(2) preparation of Escherichia coli:The picking single bacterium colony in Escherichia coli plate, it is inoculated in 5ml LB fluid nutrient mediums, puts
18-24h is cultivated in 37 DEG C, 220r/min shaking tables, 50ul bacterium solutions is drawn and expands culture in new 5ml LB fluid nutrient mediums
3h, draw 1ml bacterium solutions and centrifuge 5min in the centrifuge that rotating speed is 2000g, outwell supernatant, be resuspended with PBS, draw 200ul
In 96 orifice plates, carry out OD values using ELIASA and detect, be from bacterial concentration:2×106CFU/ml;
(3) bacteriostatic experiment step:With 96 orifice plates, it is 2 × 10 that 25ul concentration is added per hole6CFU/ml Escherichia coli bacteria liquid, then
Add culture mediums of the 25ul after step (1) processing to mix, be positioned in 37 DEG C of incubators and cultivate 3h, 200ul LB are added per hole
Fluid nutrient medium, it is incubated overnight in 37 DEG C of incubators, its OD value is detected with ELIASA within second day, according to the size of OD values, to sentence
Determine the fungistatic effect of pCMS-EGFP-PR39 expression vectors.
8. cad gene PR39 DNA murines according to claim 3, it is characterised in that the step (5) is examined including PCR
Survey and PR39 gene mRNA expressions amount detects.
9. cad gene PR39 DNA murines according to claim 3, it is characterised in that the step (8) includes as follows
Step:
(1) it is 6x10 with concentration to the transgenic lines and nontransgenic mice of acquisition5CFU/, 3x106CFU/,
6x106CFU/, 6x107The actinobacillus pleuropneumoniaes of CFU/ only are by being injected intraperitoneally transgenic mice group and non-transgenic
Mouse group;
(2) mouse treated to step (1), is cultivated, and in different time node, statistical is carried out to the death rate of mouse
Analysis.
10. cad gene PR39 DNA murines according to claim 9, it is characterised in that described pig pleuropneumonia is put
Line bar bacteria concentration is 6x106CFU/ is only.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710358833.9A CN107410206A (en) | 2017-05-19 | 2017-05-19 | A kind of cad gene PR39 DNA murines |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710358833.9A CN107410206A (en) | 2017-05-19 | 2017-05-19 | A kind of cad gene PR39 DNA murines |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107410206A true CN107410206A (en) | 2017-12-01 |
Family
ID=60425572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710358833.9A Pending CN107410206A (en) | 2017-05-19 | 2017-05-19 | A kind of cad gene PR39 DNA murines |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107410206A (en) |
-
2017
- 2017-05-19 CN CN201710358833.9A patent/CN107410206A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112695057B (en) | SARS-COV-2 antigen polypeptide and its recombinant adeno-associated virus and application in preparing vaccine | |
KR102267412B1 (en) | Rna trnascription vector and uses thereof | |
US20230043046A1 (en) | Recombinant CDKL5 Proteins, Gene Therapy and Production Methods | |
CN112501101B (en) | High-yield strain of natural herbicide thaxtomins as well as preparation method and application thereof | |
CN111575248A (en) | Lentivirus, recombinant mesenchymal stem cell and construction method and application thereof | |
JP2000139482A (en) | Attenuated bovine viral diarrhetic virus | |
CN101985477A (en) | Fusion protein for evaluating HCV NS3/4A serine proteinase inhibitor and application thereof | |
CN112980819A (en) | Construction method and application of retinitis pigmentosa animal model | |
CN107410206A (en) | A kind of cad gene PR39 DNA murines | |
CN106497960A (en) | A kind of efficient shuttle plasmid for Escherichia coli riemerella anatipestifer | |
KR102510154B1 (en) | Visceral adipose tissue macrophage-targeted gene/carrier complex for preventing or treating obesity-induced type II diabetes | |
CN111440774A (en) | Construction method of IFNGR2 gene melanoma B-16 cell line for stably expressing knock-in EGFP | |
CN113943749B (en) | Method for improving homologous recombination efficiency based on CRISPR gene editing system | |
KR102163667B1 (en) | Composite containing gene and gene delivery system for prevent or treatment of inflammatory disease | |
US6423544B1 (en) | Compositions and methods for producing recombinant virions | |
KR102570821B1 (en) | Recombinant viral vector and pharmaceutical composition incluidng thereof | |
KR101998168B1 (en) | Composite containing gene and gene delivery system for prevent or treatment of rheumatoid arthritis | |
KR101973007B1 (en) | Recombinant transition vector for enhancement of foreign protein expression | |
KR20220111294A (en) | Chimeric Opsin GPCR Protein | |
CN112759651B (en) | T cell containing chimeric antigen receptor modification and application thereof | |
CN114350721B (en) | Method for producing L-ornithine by microbial enzyme method | |
CN112831524B (en) | Artificially modified recombinant adenovirus vector, virus packaged by same and application thereof | |
CN114350698B (en) | Human recombinant arginase I production strain and construction method thereof | |
CN108085325B (en) | Glyphosate-resistant gene and cultivation method of transgenic glyphosate-resistant tobacco | |
CN101380310B (en) | Composition of bFGF modified liposome and shRNA expression vector targeting human VEGF gene and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171201 |
|
RJ01 | Rejection of invention patent application after publication |